Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: 

Articles

Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.

Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer. 

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Novel Agents Improving Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

Videos

Sangeetha Venugopal, MD, MS, provides an overview of how patients with blastic plasmacytoid dendritic cell neoplasms (BPDCN) are diagnosed.

Andrew Lane, MD, PhD, explains that blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare blood cancer that usually presents with red to purple skin lesions and requires an expert hematopathologist to diagnose using specific immunohistochemistry markers. He notes that central nervous system involvement is more common than previously thought, so all BPDCN patients should get lumbar punctures and intrathecal chemotherapy. The treatment goal is remission followed by allogeneic stem cell transplant for possible long-term remission or cure, as no therapies alone have proven sufficient. The only FDA-approved drug is tagraxofusp, though intensive ALL-like chemotherapy remains standard.

BPDCN: A Multidisciplinary Approach to Diagnosis and Treatment

Sangeetha Venugopal, MD, MS, discusses pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN). PVEK showed promising response rates in treatment-naïve BPDCN patients in an early trial and was reasonably well-tolerated without concerning safety signals. Its FDA breakthrough therapy designation in relapsed/refractory BPDCN was based on phase 1 data suggesting good efficacy even after tagraxofusp (TAG). Early trials also support PVEK's potential in CD123+ acute myeloid leukemia, both as monotherapy and when combined with other agents like azacitidine and venetoclax.

Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCN

Phyu Aung, MD, PhD, FCAP, a dermatopathologist, discusses key challenges in diagnosing and treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Definitive diagnosis is difficult given BPDCN’s heterogeneous features and frequent skin and CNS involvement. Recent advances have utilized immunophenotyping and targeted CD123, which is overexpressed on BPDCN cells. However, resistance develops with CD123 monotherapy. She notes that while testing aids BPDCN insights, more prognostic markers are needed, and emphasizes that continued cross-disciplinary research is critical to better outcomes.

Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

Dr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.

Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

EP: 1.Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

EP: 2.BPDCN: A Multidisciplinary Approach to Diagnosis and Treatment

EP: 3.Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCN

EP: 4.Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

EP: 5.Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Latest Conference Coverage